萊姆病螺旋體IgG免疫熒光玻片試劑盒

Borrelia burgdorferi IgG IFA Kit

廣州健侖生物科技有限公司

主要用途：用于檢測(cè)人血清中的萊姆病螺旋體 IgG 抗體

產(chǎn)品規(guī)格：12 孔/張,10 張/盒

包括包柔氏螺旋體菌、布魯氏菌、貝納特氏立克次體、土倫桿菌、鉤端螺旋體、新型立克次體、恙蟲(chóng)病、立克次體、果氏巴貝西蟲(chóng)、馬焦蟲(chóng)、牛焦蟲(chóng)、利什曼蟲(chóng)、新包蟲(chóng)、弓形蟲(chóng)、貓流感病毒、貓冠狀病毒、貓皰疹病毒、犬瘟病毒、犬細(xì)小病毒等病原微生物的 IFA、MIF、ELISA試劑。

萊姆病螺旋體IgG免疫熒光玻片試劑盒

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、西尼羅河、立克次體、無(wú)形體、蜱蟲(chóng)、恙蟲(chóng)、利什曼原蟲(chóng)、RK39、漢坦病毒、深林腦炎、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲(chóng)病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢(xún)

歡迎咨詢(xún)2042552662

二維碼掃一掃

【公司名稱(chēng)】 廣州健侖生物科技有限公司
【】    楊永漢 
【】 
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-3室
【企業(yè)文化】

整整一天，胰腺都在調(diào)節(jié)人體的血糖水平，通過(guò)分泌胰島素對(duì)餐后葡萄糖增加作出反應(yīng)，這有助于細(xì)胞吸收糖類(lèi)。在1型糖尿病的患者中，其自身免疫系統(tǒng)會(huì)錯(cuò)誤地殺死β細(xì)胞，而原因尚未明了，且身體不能沒(méi)有胰島素。人們通過(guò)注射仔細(xì)校準(zhǔn)劑量的胰島素來(lái)控制他們的糖尿病。但是，這與從健康胰腺獲得的精確胰島素控制幾乎無(wú)法匹配，所以研究人員幾十年來(lái)希望找到一種方法來(lái)代替失去的細(xì)胞。
當(dāng)科學(xué)家在1998年分離出人類(lèi)胚胎干細(xì)胞(ES細(xì)胞)時(shí)，希望一路飆升。ES細(xì)胞是多能的，這意味著在理論上它們可以轉(zhuǎn)變成身體的任一種細(xì)胞，包括β細(xì)胞。事實(shí)上，研究人員首要研究之一是，試圖使用ES細(xì)胞制造出胰島β細(xì)胞。后來(lái)，他們?cè)噲D使用所謂的誘導(dǎo)多能干細(xì)胞(iPS細(xì)胞)，通過(guò)將體細(xì)胞重編程成胚胎樣狀態(tài)進(jìn)行。無(wú)論哪種方式，“這被證明是一個(gè)非常復(fù)雜的工作，” 納什維爾的范德比爾特大學(xué)研究胰腺發(fā)育的馬克·麥格納遜說(shuō)。
幾個(gè)研究團(tuán)隊(duì)已經(jīng)把干細(xì)胞分化成β細(xì)胞的前體，當(dāng)放入實(shí)驗(yàn)動(dòng)物時(shí)才成熟。但這些細(xì)胞需要6周才能*成為功能性β細(xì)胞，并且它們不易在體外研究。然而，臨床試驗(yàn)已在上個(gè)月開(kāi)始測(cè)試它們用于患者的療效。

The whole day, the pancreas are regulating the body's blood sugar levels, through the secretion of insulin to respond to increased postprandial glucose, which helps cells absorb carbohydrates. In patients with type 1 diabetes, the autoimmune system kills the beta cells incorrectly, and the reason is unclear and the body can not live without insulin. People control their diabetes by carefully calibrating doses of insulin. However, this is almost impossible to match with the precise insulin control obtained from healthy pancreas, so researchers have for decades sought to find a way to replace the missing cells.
When scientists isolated human embryonic stem cells (ES cells) in 1998, they hoped to soar. ES cells are pluripotent, which means that in theory they can be transformed into any of the body's cells, including beta cells. In fact, one of the first studies of researchers was trying to make islet beta cells using ES cells. Later, they tried to use so-called induced pluripotent stem cells (iPS cells) by reprogramming somatic cells into embryoid-like states. Either way, "it turns out to be a very complex job," said Mark McNagnard at Vanderbilt University in Nashville to study pancreatic development.
Several research groups have differentiated stem cells into β-cell precursors that mature when placed in laboratory animals. However, these cells take 6 weeks to become fully functional beta cells, and they are not easy to study in vitro. However, clinical trials began testing their use in patients last month.